Taysha Gene Therapies Reports Positive Data from First Patient Dosed in Phase 1/2 Trial

Taysha Gene Therapies (Nasdaq: TSHA) has reported positive initial clinical data from the first adult Rett Syndrome patient dosed in its Phase 1/2 trial evaluating the safety and efficacy of TSHA-102. The data showed that TSHA-102 was well-tolerated with no treatment-emergent serious adverse events, and improvement in key efficacy measures four weeks post-treatment.

Taysha also reported financial results for the second quarter ended June 30, 2023, and provided a corporate update. The company Taysha successfully completed a $150 million PIPE from top-tier investors, extending its cash runway into the third quarter of 2025.

Highlights

The trial’s principal investigator observed clinical improvement in autonomic function (sleep and breathing), vocalization, gross motor skills (gained ability to sit unassisted for three minutes) and fine motor skills (gained ability to hold objects).

The company has received FDA clearance to initiate clinical development of TSHA-102 in pediatric patients in the U.S. and has submitted a  Clinical Trials Application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK for TSHA-102 in pediatric patients with Rett syndrome.

General and administrative expenses were $6.0 million for the three months ended June 30, 2023, compared to $9.9 million for the three months ended June 30, 2022.

Net loss for the three months ended June 30, 2023 was $24.6 million as compared to a net loss of $34.1 million for the three months ended June 30, 2022.

As of June 30, 2023, Taysha had $45.1 million in cash and cash equivalents.

Taysha expects to receive gross proceeds of $150 million from the Private Placement, which is expected to close August 16, 2023, before deducting placement agent commissions and offering expenses.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program. Together, we leverage our fully integrated platform with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Share This Article

 

About the Author

Taysha Gene Therapies Reports Positive Data from First Patient Dosed in Phase 1/2 Trial

Editor Prism MarketView